Welcome to our dedicated page for Amylyx Pharmaceuticals news (Ticker: AMLX), a resource for investors and traders seeking the latest updates and insights on Amylyx Pharmaceuticals stock.
Amylyx Pharmaceuticals, Inc. develops investigational therapies for endocrine conditions and neurodegenerative diseases with high unmet medical need. News about AMLX centers on its clinical-stage pipeline, including avexitide, a GLP-1 receptor antagonist being evaluated for post-bariatric hypoglycemia, and additional programs such as AMX0035, AMX0114 and AMX0318.
Recurring company updates cover clinical trial progress, expanded access activity, development-candidate selections, program discontinuations, quarterly financial results and investor presentations. Amylyx news also reflects regulatory and commercial-readiness topics tied to investigational therapies, collaboration updates and capital-runway commentary typical of a biotechnology issuer advancing multiple development programs.
Amylyx Pharmaceuticals (NASDAQ: AMLX) will have Co-CEOs Joshua Cohen and Justin Klee participate in the Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022, at 3:05 p.m. ET. The conference will take place virtually, and a live webcast can be accessed on the company's investor relations website. A replay will be available for 90 days post-event. Amylyx Pharmaceuticals is dedicated to innovating treatments for the neurodegenerative community and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals (AMLX) announced significant updates, including the FDA approval and commercial launch of RELYVRIO™ for ALS treatment in the U.S. and the ongoing launch of ALBRIOZA™ in Canada. For Q3 2022, net product revenue reached $0.3 million, primarily from ALBRIOZA sales. Research and development expenses surged to $24.9 million, and general expenses rose to $29.9 million. The net loss was $53.8 million, or $0.92 per share. Cash reserves stood at $162.6 million after an upsized public offering raised $230.8 million.
Amylyx Pharmaceuticals will announce its third quarter 2022 financial results on November 10, 2022, after U.S. market close. The management team will hold a conference call at 4:30 p.m. ET to discuss the results and company updates. Investors can access the call by dialing either (877) 870-4263 for local or (412) 317-0790 for international attendees. A live audio webcast will also be available on the company's investor website, with an archive accessible for 90 days.
Amylyx Pharmaceuticals announced the successful completion of its upsized public offering, raising $246.3 million through the sale of 7,697,812 shares at $32.00 each. The offering included the full exercise of an option for an additional 1,004,062 shares. The funds generated will support the company's efforts in developing innovative treatments for the neurodegenerative community. The offering was managed by a consortium of financial firms, including Goldman Sachs and BofA Securities.
Amylyx Pharmaceuticals has announced an upsized public offering of 6,693,750 shares of common stock, priced at $32.00 per share, expected to generate gross proceeds of $214.2 million. The offering is set to close around October 11, 2022, pending customary conditions. The company has granted underwriters a 30-day option for an additional 1,004,062 shares. Goldman Sachs, BofA Securities, SVB Securities, and Evercore ISI are the joint book-running managers of the offering. Registration statements became effective on October 6, 2022.
Amylyx Pharmaceuticals has announced a public offering of 6,000,000 shares of common stock under an S-1 registration statement filed with the SEC. The company plans to offer all shares and may grant underwriters a 30-day option to purchase an additional 900,000 shares. The offering is subject to market conditions and may not be completed as anticipated. Goldman Sachs, BofA Securities, SVB Securities, and Evercore ISI are acting as joint book-running managers.
Amylyx Pharmaceuticals announced that the FDA has approved RELYVRIO (sodium phenylbutyrate and taurursodiol) for treating adults with amyotrophic lateral sclerosis (ALS).
RELYVRIO significantly slowed physical function loss in clinical trials, offering hope for approximately 29,000 ALS patients in the U.S. with median survival from diagnosis of 2-3 years. The drug is expected to be accessible through specialty pharmacies within 4-6 weeks. Amylyx plans to support ALS patients with a dedicated care team.
Amylyx Pharmaceuticals announced that clinical data from the placebo group of the CENTAUR trial for AMX0035 are now accessible in the PRO-ACT database. This initiative supports the ALS research community by enabling collaborative efforts to uncover new treatment pathways. The PRO-ACT platform, awarded for its innovation, contains data from over 11,600 ALS participants and has been essential for numerous publications. AMX0035, under evaluation for ALS, aims to reduce neuronal cell death.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced significant preclinical data demonstrating that AMX0035, a combination of sodium phenylbutyrate and taurursodiol, has a pronounced effect on ALS-relevant molecular pathways compared to individual components. The published study in Annals of Clinical and Translational Neurology showed AMX0035 altered more genes and metabolites in fibroblasts from ALS patients than either compound alone. This underscores its potential benefits in treating ALS, a disease affecting over 90% of ALS patients.
Amylyx Pharmaceuticals has received a positive vote from the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee, with a 7:2 vote supporting the approval of AMX0035 for treating ALS. If approved, it will be the first treatment to show significant slowing of disease progression and functional decline in ALS. The final decision from the FDA is expected by September 29, 2022. The clinical trial data for AMX0035 indicated potential benefits in overall survival and was well tolerated, with the CENTAUR trial meeting its primary efficacy endpoint.